2,283 Johnson & Johnson $JNJ Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 322,735 shares of the company’s stock after selling 2,283 shares during the quarter. Johnson & Johnson makes up 1.6% of Kornitzer Capital Management Inc. KS’s investment portfolio, making the stock its 12th biggest position. Kornitzer Capital Management Inc. KS’s holdings in Johnson & Johnson were worth $85,441,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. National Pension Service raised its position in shares of Johnson & Johnson by 1.3% in the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after purchasing an additional 67,484 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after buying an additional 3,133 shares during the last quarter. Elefante Mark B grew its position in shares of Johnson & Johnson by 9.8% during the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after buying an additional 2,563 shares in the last quarter. AMG Asset Management Group Inc. grew its position in shares of Johnson & Johnson by 172.0% during the third quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock worth $1,020,000 after buying an additional 2,436 shares in the last quarter. Finally, Gradient Investments LLC increased its stake in shares of Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after buying an additional 13,737 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HSBC upped their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. Sanford C. Bernstein set a $270.00 target price on shares of Johnson & Johnson in a research report on Thursday, October 15th. Scotiabank restated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $276.14 on Friday. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $282.02. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm has a market cap of $664.76 billion, a price-to-earnings ratio of 41.84, a PEG ratio of 2.73 and a beta of 0.22. The stock has a 50 day moving average of $265.91 and a 200-day moving average of $248.30.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period in the prior year, the company posted $2.80 EPS. The business’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s payout ratio is presently 81.21%.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.